Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

TransPerineal Laser Ablation (TPLA) Treatment of Focal Low-Intermediate Risk Prostate Cancer

Guglielmo Manenti
* ORCID logo ,
Tommaso Perretta
,
Marco Nezzo
,
Federico Romeo Fraioli
,
Beatrice Carreri
,
Paola Elda Gigliotti
ORCID logo ,
Andrea Micillo
,
Andrea Malizia
ORCID logo ,
Daniele Di Giovanni
ORCID logo ,
Colleen Patricia Ryan
,
Francesco Giuseppe Garaci
Version 1 : Received: 27 February 2024 / Approved: 27 February 2024 / Online: 28 February 2024 (04:48:26 CET)

How to cite: Manenti, G.; Perretta, T.; Nezzo, M.; Fraioli, F.R.; Carreri, B.; Gigliotti, P.E.; Micillo, A.; Malizia, A.; Di Giovanni, D.; Ryan, C.P.; Garaci, F.G. TransPerineal Laser Ablation (TPLA) Treatment of Focal Low-Intermediate Risk Prostate Cancer. Preprints 2024, 2024021578. https://doi.org/10.20944/preprints202402.1578.v1 Manenti, G.; Perretta, T.; Nezzo, M.; Fraioli, F.R.; Carreri, B.; Gigliotti, P.E.; Micillo, A.; Malizia, A.; Di Giovanni, D.; Ryan, C.P.; Garaci, F.G. TransPerineal Laser Ablation (TPLA) Treatment of Focal Low-Intermediate Risk Prostate Cancer. Preprints 2024, 2024021578. https://doi.org/10.20944/preprints202402.1578.v1

Abstract

Background: this interventional pilot study aimed to evaluate the short-term (3 years) efficacy of focal laser ablation (FLA) in treating the index lesion of low-intermediate risk prostate cancer, along with assessing the safety of the procedure (ClinicalTrials.gov ID NCT04045756). Methods: forty patients aged between 46 and 86 with histologically proven organ-confined prostate cancer and low to intermediate progression risk were included. FLA was performed under percutaneous fusion magnetic resonance/ultrasound guidance in a Day Hospital setting under local anesthesia. Patients underwent regular clinical assessments, PSA measurements, post-procedure MRI scans, and biopsies at 36 months or if positive findings were detected earlier. Statistical analyses were conducted to assess trends in PSA levels and cavity dimensions over time. Results: forty patients were initially included, with 15 lost to follow-up. At 36 months, a mean PSA reduction of 60% was observed, and 80% of MRI scans showed no signs of in-field clinically significant residual/recurrent cancer. Biopsies at 36 months revealed no malignant findings in 20 patients. No deterioration in sexual function or urinary symptoms was recorded. Conclusions: FLA appears to be safe, feasible and effective in the index lesion treatment of low-intermediate risk prostate cancer, with a high rate of tumor eradication and preservation of quality of life.

Keywords

mpMRI; prostate cancer; TPLA; FLA; focal laser ablation; transperineal laser ablation

Subject

Medicine and Pharmacology, Urology and Nephrology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.